Dow makes $1.5bn divestiture plans


US chemical giant Dow has announced plans to sell more parts of its ‘non-core’ business, adding that it will target ‘an increased divestiture list of nearly $1.5 billion (£1 billion) over the next 18 months’.

The company had identified two parts in particular: the ‘polypropylene licensing and catalysts’ business unit and the plastics additives unit.

‘We are reviewing our entire portfolio and seeking even further opportunities to optimise value: selectively pruning assets that are no longer a strategic or financial fit,’ said Dow chair and chief executive Andrew Liveris.

In October 2012, Dow announced plans to cut 2400 jobs, representing 5% of its global workforce, and close 20 manufacturing plants, in a bid to shave $500 million off its annual costs over the next two years. Since then, it has struck deals to sell the stabilisers component of its plastics additives business and its 50% stake ownership in Nippon Unicar Company – a Japanese joint venture with Tonen Chemical.


Related Content

'Safe antifreeze' works better with added nanoparticles

26 March 2015 Research

news image

Antifreezes based on a non-toxic food additive are now more effective and user-friendly

Copper catalysis sees the light

28 March 2013 Research

news image

Copper nanoparticle's oxidation state can be tuned using visible light, enabling industrially important propylene epoxidation

Most Read

Flushing advice is flawed

24 August 2015 Research

news image

Protocols to restore contaminated water supplies are not based on science

Simple chemistry saving thousands of gold miners from mercury poisoning

25 August 2015 News and Analysis

news image

Basic apparatus is cutting mercury pollution and helping Indonesian miners go for gold

Most Commented

Paper device tracks fracking pollution

21 August 2015 Research

news image

Cheap and simple bromide sensor warns if water has been contaminated with fracking fluid

New drug treatment for alcoholism shows promise in animal studies

24 August 2015 Research

news image

Compounds that target a receptor in the brain appear less addictive with fewer negative side-effects than existing drugs